UK markets close in 6 hours 52 minutes

Quince Therapeutics, Inc. (QNCX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.0300-0.0300 (-2.83%)
At close: 04:00PM EDT
1.0100 -0.02 (-1.94%)
After hours: 04:06PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 44.51M
Enterprise value -16.73M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.52
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.62

Trading information

Stock price history

Beta (5Y monthly) 1.25
52-week change 3-32.68%
S&P500 52-week change 321.08%
52-week high 31.7400
52-week low 30.8400
50-day moving average 31.1513
200-day moving average 31.1596

Share statistics

Avg vol (3-month) 371.69k
Avg vol (10-day) 3136.82k
Shares outstanding 543.22M
Implied shares outstanding 643.22M
Float 827.05M
% held by insiders 117.06%
% held by institutions 128.17%
Shares short (15 Apr 2024) 41.86M
Short ratio (15 Apr 2024) 429.06
Short % of float (15 Apr 2024) 45.09%
Short % of shares outstanding (15 Apr 2024) 44.30%
Shares short (prior month 15 Mar 2024) 41.86M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-11.33%
Return on equity (ttm)-33.81%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -24.32M
Net income avi to common (ttm)-31.39M
Diluted EPS (ttm)-0.8400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)75.06M
Total cash per share (mrq)1.74
Total debt (mrq)13.81M
Total debt/equity (mrq)16.24%
Current ratio (mrq)8.09
Book value per share (mrq)1.98

Cash flow statement

Operating cash flow (ttm)-18.29M
Levered free cash flow (ttm)-1.94M